FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 11 2020 - 8:00AM
FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual
SVB Leerink Global Healthcare Conference on February 25, 2020.
Enrique Conterno, Chief Executive Officer, will participate in a
fireside chat at 3:30 PM Eastern Time. A live audio webcast will be
available on the “Events & Presentations” section of the
FibroGen website at www.fibrogen.com. A replay of the webcast will
be available for 30 days.
About FibroGen FibroGen, Inc., headquartered in
San Francisco, California, with subsidiary offices in Beijing and
Shanghai, People’s Republic of China, is a leading
biopharmaceutical company discovering and developing a pipeline of
first-in-class therapeutics. The company applies its pioneering
expertise in hypoxia-inducible factor (HIF) and connective tissue
growth factor (CTGF) biology, and clinical development to advance
innovative medicines for the treatment of anemia, fibrotic disease,
and cancer. Roxadustat, the company’s most advanced product, is an
oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH)
activity, completing worldwide Phase 3 clinical development for the
treatment of anemia in chronic kidney disease (CKD), is approved by
the National Medical Products Administration (NMPA) in China for
CKD patients on dialysis and not on dialysis, and by the Ministry
of Health, Labour and Welfare (MHLW) in Japan for CKD patients on
dialysis. The NDA for roxadustat for treatment of CKD anemia was
submitted to the U.S. FDA in December 2019. Roxadustat is in Phase
3 clinical development in the U.S. and Europe and in Phase 2/3
development in China for anemia associated with myelodysplastic
syndromes (MDS), and in a Phase 2 U.S. trial for treatment of
chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in Phase 3 clinical development for the
treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic
cancer, and is currently in a Phase 2 trial for Duchenne muscular
dystrophy (DMD). FibroGen is also developing a biosynthetic cornea
in China. For more information, please visit www.fibrogen.com.
Contact: FibroGen, Inc.
Media Inquiries: Sara Iacovino 1.703.474.4452
sara.iacovino@gcihealth.com
Investors: Michael Tung, M.D. Investor
Relations 1.415.978.1433 ir@fibrogen.com
Source: FibroGen, Inc
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2024 to May 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From May 2023 to May 2024